EP2268639A2 - Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate - Google Patents

Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate

Info

Publication number
EP2268639A2
EP2268639A2 EP09751575A EP09751575A EP2268639A2 EP 2268639 A2 EP2268639 A2 EP 2268639A2 EP 09751575 A EP09751575 A EP 09751575A EP 09751575 A EP09751575 A EP 09751575A EP 2268639 A2 EP2268639 A2 EP 2268639A2
Authority
EP
European Patent Office
Prior art keywords
varenicline
tosylate
base
crystalline form
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09751575A
Other languages
German (de)
French (fr)
Inventor
Suhail Ahmad
Vinod Kumar Kansal
Maytal Piran
Zvi Harel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP2268639A2 publication Critical patent/EP2268639A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Crystalline forms of Varenicline Tosylate, processes for preparing those crystalline forms of Varenicline Tosylate, and processes for obtaining high purity Varenicline base using Varenicline Tosylate are provided.

Description

VARENICLINE TOSYLATE. AN INTERMEDIATE IN THE PREPARATION PROCESS OF VARENICLINE L-TARTRATE
RELATED APPLICATIONS
[0001] This application claims benefit of U.S. Provisional Patent
Applications Nos. 61/153,390, filed February 18, 2009, 61/190,284, filed August 26, 2008, 61/135,359, filed July 17, 2008, and 61/128,649, filed May 22, 2008, the contents of which are incorporated herein in their entirety by reference.
FIELD OF INVENTION
[0002] The present invention is directed to crystal forms of Varenicline
Tosylate, methods for the preparation of the crystal forms, and processes for preparing high purity Varenicline base from Varenicline Tosylate.
BACKGROUND OF THE INVENTION
[0003] Varenicline tartrate salt, 7,8,9,10-tetrahydro-6,10-rnethano-6 H - pyrazino[2,3-h][3]benzazepine, (2 R ,3 R )-2,3-dihydroxybutanedioate (1 :1), has a molecular weight of 361.35 Daltons and is described according to the following formula:
[0004] Varenicline tartrate is marketed by Pfizer under the trade name of
CHANTIX™ as a partial agonist selective for certain subtypes of nicotinic receptors and indicated for smoking cessation. [0005] Varenicline base and a variety of salts thereof are disclosed in
U.S. Patent No. 6,410,550, EP 1044189, and EP 1659114.
[0006] Crystalline forms of Varenicline citrate and succinate salts are described in the US Patents No. 6,787,549 and 6,794,388, respectively.
[0007] Varenicline L-tartrate and its crystalline forms A, B, and C are described in the U.S. Patents Nos. 6,890,927 and 7,265,119.
SUMMARY OF THE INVENTION
[0008] The present invention provides crystal forms of Varenicline Tosylate,
5,8,14-Triazatetracyclo [10.3.1.02'π.04j9]hexadeca-2(ll),335,7,9-pentaene tosylate, having the following formula:
methods of preparing the crystal forms of Varenicline Tosylate of the invention, and processes for preparing high purity Varenicline base from Varenicline Tosylate. [0009] Varenicline Tosylate is preferably isolated as a solid, more preferably as solid and even more preferably as a crystal form. [00010] Varenicline Tosylate described above can be characterized by data selected from 1HNMR spectrum (400MHz, DMSO- d6) having peaks at about δ. 8.931-8.050 (4H), 7.47-7.12 (4H), 3.6 (br s 2H), 3.49-3.18 (4H), and 2.293-2.191
(5H), a 13CNMR spectrum (100.61MHz, DMSO- d6) having peaks at about δ. 150.97, 148.20, 143.12, 133.36, 130.68, 129.32 ,53.83, 51.96, 45.28, 45.08, 43.26, and 26.00, an 1HNMR spectrum as depicted in Figure 1, a 13CNMR spectrum as depicted in Figure 2, and combinations thereof.
[00011] Varenicline Tosylate can be prepared by combining Varenicline base, a solvent and p-Toluene sulfonic acid (p-TSA) to obtain a reaction mixture and precipitating Varenicline Tosylate from the reaction mixture. Preferably, the obtained Varenicline Tosylate is further recovered from the reaction mixture. [00012] Varenicline base, p-TSA and at least one solvent can be combined to form a reaction mixture at about room temperature. Varenicline Tosylate then precipitates out of the mixture.
[00013] A reaction mixture of p-TSA, Varenicline base, and a solvent may be heated and further cooled to facilitate precipitation of Varenicline Tosylate. [00014] The present invention provides a crystalline form of Varenicline
Tosylate, designated form I, characterized by data selected from a group consisting of a powder XRD pattern having peaks at about 10.1, 13.0, and 18.7 ± 0.2 degrees two theta and at least two peaks selected from the group consisting of 11.5, 14.2, 16.7, 19.3, and 20.6 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 10.1, 13.0, 16.7, 18.7 and 20.6 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 10.2, 13.1, 16.8, 19.4, 23.0 ± 0.1 degrees two theta, a powder XRD pattern substantially as depicted in figures 4 and 5, and combinations thereof. [00015] The above crystalline form I may be further characterized by additional peaks selected from a group consisting of a powder XRD pattern having peaks at about 11.5, 14.2, 17.4, 19.3 and 22.3 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 14.3, 18.5, 18.9, 23.5 and 26.8 ± 0.1 degrees two theta and combinations thereof.
[00016] Crystalline form I of Varenicline Tosylate may be prepared by a process comprising; combining Varenicline Base, a Ci-C6 alcohol and p-Toluene sulfonic acid to obtain a reaction mixture, heating and then cooling the obtained reaction mixture.
[00017] Alternatively, crystalline form I of Varenicline Tosylate may be prepared by a process comprising heating a mixture of Varenicline Base in a Ci-C6 alcohol and p-TSA, and further cooling the mixture.
[00018] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form II, characterized by data selected from a group consisting of a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 20.8, and 21.3 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 21.3 and 23.3 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 5.8, 10.0, 17.4, 19.1, 23.3 ± 0.1 degrees two theta, a powder XRD pattern substantially as depicted in figures 6 and 7 and combinations thereof.
[00019] The above crystalline form II may be further characterized by additional peaks selected from a group consisting of a powder XRD pattern having peaks at about 5.8, 10.0, 16.9, 17.4, and 18.8 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 11.5, 13.2, 20.8, 22.5 and 25.4 ± 0.1 degrees two theta, and combinations thereof.
[00020] Crystalline form II of Varenicline Tosylate may be prepared by a process comprising; combining Varenicline Base, methanol, a C6-Ci2 aromatic hydrocarbon, and p-Toluene sulfonic acid to obtain a reaction mixture, heating and cooling the obtained reaction mixture.
[00021 ] Alternatively, crystalline form II of Varenicline Tosylate may be prepared by a process comprising heating a mixture of Varenicline base in methanol,
Cβ-Ci2 aromatic hydrocarbon, and p-TSA, and cooling the mixture.
[00022] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form HI, characterized by a powder XRD pattern having peaks at about 10.0, 11.6, 17.4, 22.3, and 22.8 ± 0.2 degrees two theta and additional peaks at about 5.8, 18.8, 19.3, 20.8, and 23.2 ± 0.2 degrees two theta, as depicted in the PXRD diffraction of Figures 8, 9 and/or 10.
[00023] In particular, Varenicline Tosylate form III can be characterized by a powder XRD pattern having peaks at about 10.0, 11.6, 17.4, 22.3, and 22.8 ± 0.2 degrees two theta.
[00024] The Varenicline Tosylate form III described above can be further characterized by data selected from the group consisting of a powder XRD pattern having peaks at about 5.8, 18.8, 19.3, 20.8, and 23.2 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 5.9, 18.9, 19.3, 20.8 and 26.4 ± 0.2 degrees two theta and combinations thereof.
[00025] The present invention also provides a process for preparing
Varenicline Tosylate form HI, comprising exposing Varenicline Tosylate form II to less than about 5 percent relative humidity, for a period sufficient to convert form II to form III. Preferably, the relative humidity is 0 percent.
[00026] The present invention also provides a process for preparing
Varenicline Tosylate form HI by heating Varenicline Tosylate form II for a period sufficient to convert form II to form HI. The heating is preferably to a temperature of about 700C to about 1000C, and more preferably to about 8O0C.
[00027] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form IV, characterized by a powder XRD pattern having peaks at about 11.6, 13.2, 19.5, 23.0, and 24.4 ± 0.2 degrees two theta and additional peaks at about 10.3, 16.9, 18.9, 20.7, and 22.5 ± 0.2 degrees two theta as depicted in the PXRD diffraction of Figures 11 and 12.
[00028] In particular, Varenicline Tosylate form IV can be characterized by a powder XRD pattern having peaks at about 11.6, 13.2, 19.5, 23.0, and 24.4 ± 0.2 degrees two theta.
[00029] The Varenicline Tosylate form IV described above can be further characterized by apowder XRD pattern having peaks at about 10.3, 16.9, 18.9, 20.7, and 22.5 ± 0.2 degrees two theta.
[00030] The present invention provides a process for preparing Varenicline
Tosylate form IV, comprising: combining Varenicline base, a Cj-C6 alcohol, a C1-C3 halogenated aliphatic hydrocarbon and p-Toluene sulfonic acid (p-TS A) to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture.
[00031] The present invention also provides a process for preparing
Varenicline Tosylate form IV, comprising wetting Varenicline Tosylate form II with water, and grinding the wetted material. Preferably about 100 mg to about 200 mg
Varenicline Tosylate form H is wetted with about 1 to about 2 drops of water.
[00032] The present invention also provides a process for preparing
Varenicline Tosylate form IV, comprising exposing Varenicline Tosylate form II to a relative humidity of from about 80 percent to about 100 percent for a period sufficient to convert form II to form TV. Preferably, the exposure is for a period of about 1 to about 15 days. More, preferably, for about 1 day.
[00033] The present invention encompasses pure Varenicline Tosylate.
Preferably, the Varenicline Tosylate of the present invention has a total purity of greater than 97 percent by area HPLC, more preferably greater than 99 percent, and even more preferably 99.99 percent by area HPLC.
[00034] The present invention further encompasses pure Varenicline base.
Preferably, the Varenicline base of the present invention has a total purity of greater than 97 percent by area HPLC, more preferably greater than 99 percent, and even more preferably the purity if 99.97 percent by area HPLC.
[00035] The present invention also provides a process for obtaining pure
Varenicline base, comprising slurrying Varenicline Tosylate in water with a base and an inert organic solvent. Preferably, the water used is demineralized water (DM water). [00036] Varenicline base obtained according to the process described above is preferably obtained with a total purity of greater than 97 percent by area HPLC, more preferably with a purity of 99.97 percent by area HPLC.
[00037] Optionally, the pure Varenicline base obtained according to the process described above is precipitated from the reaction mixture with an organic solvent.
[00038] The present invention also provides a process for preparing
Varenicline L-Tartrate, comprising obtaining a Varenicline Tosylate according to any of the processes described above, and converting it to Varenicline L-Tartrate.
BRIEF DESCRIPTION OF THE FIGURES
[00039] Figure 1 illustrates 1H NMR spectrum of Varenicline Tosylate.
[00040] Figure 2 illustrates 13C NMR spectrum of Varenicline Tosylate.
[00041 ] Figure 3 illustrates 13C NMR DEPT spectrum of Varenicline
Tosylate.
[00042] Figure 4 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form I obtained in example 3.
[00043] Figure 5 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form I obtained in example 6, where the peak at 28.45 degrees two theta is attributed to silicon.
[00044] Figure 6 illustrates a PXRD pattern of crystalline Varenicline
Tosylate form II obtained in example 7.
[00045] Figure 7 illustrates a PXRD pattern of crystalline Varenicline
Tosylate form II, where the peak at 28.45 degrees two theta is attributed to silicon. [00046] Figure 8 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form HI obtained in example 8.
[00047] Figure 9 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form III obtained in example 9.
[00048] Figure 10 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form in obtained in example 10.
[00049] Figure 11 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form IV obtained in example 11.
[00050] Figure 12 illustrates a PXRD pattern of crystalline Varenicline
Tosylate_form IV obtained in example 12. [00051] Figure 13 illustrates a PXRD pattern of crystalline Varenicline
Tosylate form TV" obtained in example 14, where the peak at 28.45 degrees two theta is attributed to silicon.
DETAILED DESCRIPTION OF THE INVENTION
[00052] The present invention provides crystal forms of Varenicline Tosylate,
5,8,14-Triazatetracyclo [10.3.1.02'11.04'9]hexadeca-2(l l),3,5,7,9-pentaene tosylate, having the following formula:
methods of preparing the crystal forms of Varenicline Tosylate of the invention, and processes for preparing high purity Varenicline base from Varenicline Tosylate.
[00053] As used herein, "Varenicline base product" refers to the Varenicline base obtained following the conversion of Varenicline Tosylate to Varenicline base.
[00054] Varenicline Tosylate is preferably isolated as a solid and more preferably as a crystal form. The use of Varenicline Tosylate as an intermediate salt for preparation of Varenicline base, 5,8,14-Triazatetracyclo[10.3.1.02'11.04'9] hexadeca-2(ll),3,5,7,9-pentaene, having the following formula:
allows obtaining such Varenicline base in a relatively high purity. The purer Varenicline base obtained according to the present invention may be further converted to Varenicline L-tartrate salt. [00055] Varenicline Tosylate described above can be characterized by data selected from a IHNMR spectrum (400MHz, DMSO- d6) having peaks at about δ. 8.931-8.050 (4H), 7.47-7.12 (4H)5 3.6 (br s 2H), 3.49-3.18 (4H) and 2.293-2.191 (5H), a 13CNMR spectrum (100.61MHz, DMSO- d6) having peaks at about δ. 150.97, 148.20, 143.12, 133.36, 130.68, 129.32 ,53.83, 51.96, 45.28, 45.08, 43.26 and 26.00, a ^HNMR spectrum as depicted in Figure 1, a 13Qsj]y[R spectrum as depicted in Figure 2, and combinations thereof.
[00056] Varenicline Tosylate may be prepared by combining Varenicline base, a solvent, and p-Toluene sulfonic acid (p-TSA) to create a reaction mixture. Varenicline Tosylate forms in such reaction mixture through contact of Varenicline base with p-TSA.
[00057] A solution or a suspension of Varenicline base, a solvent and p-TSA may be combined to form a reaction mixture, followed by precipitation and recovery of the Varenicline Tosylate salt from the mixture. The p-TSA may be added either as a solid or as a solution or suspension in a solvent. The organic solvent present in the reaction mixture is preferably selected from the group consisting OfCi-8 alcohols, C3-7 esters, C3-8 ethers, C3-7 ketones, C6-12 aromatic hydrocarbons, acetonitrile, water, and mixtures thereof. Preferably, the solvent is selected from Ci-8 alcohols and C6-I2 aromatic hydrocarbons. More preferably, the solvent is selected from isopropyl alcohol (EPA), methanol, toluene, and mixtures thereof.
[00058] Varenicline base, p-TSA, and at least one solvent may be combined to form a reaction mixture at about room temperature (in this application the term "room temperature" encompasses a range of preferably about 150C to about 250C). The amount of p-TSA present in such reaction mixture is preferably to the point of saturation. Varenicline Tosylate then precipitates out of the mixture. Such precipitation may occur on its own or be induced. The reaction mixture may be stirred before, during, or after precipitation.
[00059] P-TSA and Varenicline base and at least one solvent may be combined to form a reaction mixture, which is further heated and then cooled to facilitate precipitation of Varenicline Tosylate. Heating may be carried out from about room temperature to about the reflux temperature of the solvent. Cooling is generally to a temperature of about 5O0C or less, preferably about room temperature, to facilitate precipitation. The reaction mixture may be stirred before, during, or after precipitation.
[00060] The resulting precipitate from any of the above embodiments may be recovered by various techniques, such as filtration. The precipitate may be dried under ambient or reduced pressure (pressure of less then about one atmosphere), and/or elevated temperature. The precipitate may be dried at room temperature at a pressure of about 400 to about 750 mm Hg and a temperature of about 400C to about 70°C.
[00061] In accordance with the invention, Varenicline Tosylate can be prepared in different polymorphic forms. Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, such as Varenicline Tosylate may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, X-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum. One crystalline form may give rise to thermal behavior different from that of another crystalline form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis ("TGA"), and differential scanning calorimetry ("DSC"), which have been used to distinguish polymorphic forms.
[00062] The difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula, yet having distinct physical properties that can be advantageous in certain applications compared to other crystalline forms of the same compound or complex. Therefore, processes for the preparation of polymorphic forms of Varenicline Tosylate are desirable.
[00063] The present invention provides a crystalline form of Varenicline
Tosylate, designated form I, characterized by data selected from a group consisting of a powder XRD pattern having peaks at about 10.1, 13.0, and 18.7 ± 0.2 degrees two theta and at least two peaks selected from the group consisting of 11.5, 14.2, 16.7, 19.3, and 20.6 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 10.1, 13.0, 16.7, 18.7 and 20.6 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 10.2, 13.1, 16.8, 19.4, 23.0 ± 0.1 degrees two theta, apowderXRD pattern substantially as depicted in Figures 4 and 5, and combinations thereof. As noted above in the description of the drawings, Figure 5 illustrates a powder XRD pattern of Varenicline Tosylate form I mixed with silicon, where the silicon is added as an internal standard, having a powder XRD peak corrected to be 28.45 degrees two theta. [00064] The above crystalline form I may be further characterized by additional peaks selected from a group consisting of a powder XElD pattern having peaks at about 11.5, 14.2, 17.4, 19.3 and 22.3 ± 0.2 degrees two theta, a powder XKD pattern having peaks at about 14.3, 18.5, 18.9, 23.5 and 26.8 ± 0.1 degrees two theta and combinations thereof.
[00065] Crystalline form I of Varenicline Tosylate may be prepared by a process comprising combining Varenicline Base, a C1-Ce alcohol, and p-Toluene sulfonic acid to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture.
[00066] Alternatively, crystalline form I of Varenicline Tosylate may be prepared by a process comprising heating a mixture of Varenicline Base in a Ci-C6 alcohol and p-TSA, and further cooling the mixture.
[00067] Preferably, the alcohol used in the process described above is isopropyl alcohol (IPA) or methanol. Most preferably, it is methanol.
[00068] Heating in the process described above may be to a temperature of from about 65°C to about 85°C, more preferably from about 65°C to about 75°C, and more preferably from about 65 °C to about 7O0C.
[00069] Cooling in the process described above is from a temperature of about
35°C to about 00C, more preferably, from about 35°C to 15°C, and, more preferably, from about 320C to 280C.
[00070] In one specific embodiment, Varenicline base in methanol is heated to a temperature of about 650C to about 700C, p-TSA is added, and the mixture is then cooled to a temperature of about 280C to about 32°C.
[00071] Additionally, crystalline form I of Varenicline Tosylate may be prepared by heating crystalline form II of Varenicline Tosylate characterized below, for a period sufficient to convert form II to form I.
[00072] Heating of form II is to a temperature of about 25°C to about 215°C.
Preferably, heating is to about 1000C to 215°C, more preferably to a temperature of about 8O0C to 21O0C, and most preferably to about 21O0C. Preferably, heating of form π is performed in a closed crucible of a Differential Scanning Calorimeter
(DSC).
[00073] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form II, characterized by data selected from a group consisting of a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 20.8, and 21.3 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 21.3 and 23.3 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 5.8,
10.0, 17.4, 19.1, 23.3 ± 0.1 degrees two theta, a powder XRD pattern substantially as depicted in Figures 6 and 7 and combinations thereof. As noted above in the description of the drawings, Figure 7 illustrates a powder XRD pattern of Varenicline
Tosylate form II mixed with silicon, where the silicon is added as an internal standard, having a powder XRD peak corrected to be 28.45 degrees two theta.
[00074] The above crystalline form II may be further characterized by additional peaks selected from a group consisting of a powder XRD pattern having peaks at about 5.8, 10.0, 16.9, 17.4, and 18.8 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 11.5, 13.2, 20.8, 22.5 and 25.4 ± 0.1 degrees two theta, and combinations thereof.
[00075] Crystalline form II of Varenicline Tosylate may be prepared by a process comprising; combining Varenicline Base, methanol, a C6-Ci2 aromatic hydrocarbon, and p-Toluene sulfonic acid to obtain a reaction mixture, and heating and cooling the obtained reaction mixture.
[00076] Alternatively, crystalline form II of Varenicline Tosylate may be prepared by a process comprising heating a mixture of Varenicline base in methanol,
C6-Ci2 aromatic hydrocarbon, and p-TSA, and cooling the mixture.
[00077] The C6-Ci2 aromatic hydrocarbon used in the process described above can be toluene or xylene (can be used is a form of meta-xylene, ortho-xylene, para-xylene and mixtures thereof). More preferably, toluene is used.
[00078] Varenicline base is preferably used in a mixture of about 15 percent to about 30 percent volume C6-Ci2 aromatic hydrocarbon and about 70 percent to about 85 percent volume methanol.
[00079] Heating in the process described above may be to a temperature of from about 650C to about 700C.
[00080] Cooling in the process described above is from a temperature of about
30°C to about 2O0C.
[00081] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form HI, characterized by a powder XRD pattern having peaks at about 10.0, 11.6, 17.4, 22.3, and 22.8 ± 0.2 degrees two theta and additional peaks at about 5.8, 18.8, 19.3, 20.8, and 23.2 ± 0.2 degrees two theta, as depicted in the PXRD diffraction of Figures 8, 9 and/or 10. As noted above in the description of the drawings, Figure 10 illustrates a powder XRD pattern of Varenicline Tosylate form
III mixed with silicon, where the silicon is added as an internal standard, having a powder XKD peak corrected to be 28.45 degrees two theta.
[00082] In particular, Varenicline Tosylate form III can be characterized by a powder XRD pattern having peaks at about 10.0, 11.6, 17.4, 22.3, and 22.8 ± 0.2 degrees two theta.
[00083] The Varenicline Tosylate form III described above can be further characterized by data selected from the group consisting of a powder XRD pattern having peaks at about 5.8, 18.8, 19.3, 20.8, and 23.2 ± 0.2 degrees two theta, a powder XRD pattern having peaks at about 5.9, 18.9, 19.3, 20.8 and 26.4 ± 0.2 degrees two theta and combinations thereof.
[00084] The present invention also provides a process for preparing
Varenicline Tosylate form m, comprising exposing Varenicline Tosylate form II to less than about 5 percent relative humidity, for a period sufficient to convert form II to form IE.
[00085] The relative humidity used in the process described above is preferably 0 percent.
[00086] As used herein, a "sufficient" period necessary to obtain a desired polymorphic form can be determined by periodically measuring a sample by powder
XRD until the desired polymorphic form is obtained.
[00087] Preferably, Varenicline Tosylate is exposed in the above process to 0 percent relative humidity for a period of about 1 to about 15 days, more preferably, for about 1 to about 10 days, more preferably, for about 1 to about 7 days, and, most preferably, 2 days.
[00088] The above process is preferably performed at room temperature.
[00089] The present invention also provides a process for preparing
Varenicline Tosylate form III by heating Varenicline Tosylate form II for a period sufficient to convert form II to form III.
[00090] The heating described in the process above is preferably to a temperature of about 70°C to about 1000C, more preferably, to about 75°C to about
85°C, and, more preferably, to about 8O0C.
[00091 ] Preferably, the Varenicline Tosylate is heated for a period of about half an hour to about two hours, more preferably for about one hour. [00092] The present invention also provides a crystalline form of Varenicline
Tosylate, designated form IV, characterized by a powder XRD pattern having peaks at about 11.6, 13.2, 19.5, 23.0, and 24.4 ± 0.2 degrees two theta and additional peaks at about 10.3, 16.9, 18.9, 20.7 and 22.5 ± 0.2 degrees two theta as depicted in the PXRD diffraction of Figures 11 and 12. As noted above in the description of the drawings, Figure 12 illustrates a powder XRD pattern of Varenicline Tosylate form IV mixed with silicon, where the silicon is added as an internal standard, having a powder XRD peak corrected to be 28.45 degrees two theta.
[00093] In particular, Varenicline Tosylate form IV can be characterized by a powder XRD pattern having peaks at about 11.6, 13.2, 19.5, 23.0, and 24.4 ± 0.2 degrees two theta.
[00094] The Varenicline Tosylate form IV described above can be further characterized by a powder XRD pattern having peaks at about 10.3, 16.9, 18.9, 20.7, and 22.5 ± 0.2 degrees two theta.
[00095] The present invention provides a process for preparing Varenicline
Tosylate form IV, comprising combining Varenicline base, a C1-CO alcohol, a Ci-C3 halogenated aliphatic hydrocarbon, and p-Toluene sulfonic acid (p-TSA) to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture. [00096] Preferably, the C1-Cn alcohol used in the process described above is isopropyl alcohol (IPA) or methanol. Most preferably, it is methanol. [00097] Preferably, the C1-C3 halogenated aliphatic hydrocarbon is methylene di-chloride (MDC) or ethylene dichloride. Most preferably, it is MDC. [00098] Heating in the process described above may be to a temperature of from about 65°C to about 85°C, more preferably, from about 65°C to about 750C, and, most preferably, from about 65°C to about 700C.
[00099] Cooling in the process described above is from a temperature of about
35°C to about 1O0C, more preferably, from about 350C to 20°C, and, most preferably, from about 3O0C to 25°C.
[000100] The present invention also provides a process for preparing
Varenicline Tosylate form TV, comprising wetting Varenicline Tosylate form II with water, and grinding the wetted material.
[000101] As used herein, 'wetting' refers to damping about 100 mg to about
200 mg Varenicline Tosylate with about 1 to about 2 drops of water, where a drop of water refers to about 0.1 ml to about 0.25 ml of water. [000102] Preferably, the wet Varenicline Tosylate is ground for a period of about 1 minute to about 5 minutes, and, more preferably, for about 1 minute.
[000103] Preferably, the wet Varenicline Tosylate is ground using a mortar and pestle. The time frame and equipment used for grinding can be modified for use on industrial scale.
[000104] The present invention also provides a process for preparing
Varenicline Tosylate form IV, comprising exposing Varenicline Tosylate form II to a relative humidity of from about 80 percent to about 100 percent for a period sufficient to convert form II to form IV.
[000105] Preferably, the exposure in the above process was performed for a period of about 1 to about 15 days, more preferably, for about 1 to about 10 days, more preferably for about 1 to about 7 days, and most preferably, 1 day.
[000106] In one specific embodiment, Varenicline Tosylate form II is exposed to a relative humidity of about 100 percent for a period of about 1 day at room temperature to obtain Varenicline Tosylate form IV.
[000107] As used herein, "pure Varenicline Tosylate" or "pure Varenicline
Base" refers to total chemical purity of Varenicline Tosylate/Base as measured by area HPLC.
[000108] hi one embodiment, the present invention encompasses pure
Varenicline Tosylate.
[000109] Preferably, the Varenicline Tosylate obtained according to any of the processes described above has a total purity of greater than 97 percent by area HPLC.
More preferably, greater than 99 percent. Most preferably, the Varenicline Tosylate has a total purity of 99.99 percent by area HPLC.
[000110] A repetition of U.S. Patent No. 6,410,550 Example 26C, with the exception of an additional extraction with MDC, provided Varenicline base having a total purity of 96.3 percent. The present invention provides a process for obtaining pure Varenicline Tosylate, having a purity greater than 97 percent, or greater than 98 percent, or greater than 99 percent, which is further converted to pure Varenicline base. We observed that the present invention allows obtaining Varenicline base with a total purity of greater than 99.9 percent.
[000111] In particular, it has been found that Varenicline Tosylate formed from
Varenicline base has a higher purity than the Varenicline base starting material, and the conversion of the Varenicline Tosylate back to Varenicline base provides a
Varenicline base having a higher purity than the Varenicline base starting material.
[000112] Therefore, the present invention encompasses pure Varenicline base.
[000113] The present invention provides a process for obtaining pure
Varenicline base, comprising slurrying Varenicline Tosylate in water with a base and an inert organic solvent. Preferably, the Varenicline Tosylate used to produce the
Varenicline base is first prepared from Varenicline base.
[000114] Alternatively, the present invention provides a process for obtaining pure Varenicline base, comprising combining Varenicline Tosylate in the presence of a base and an inert organic solvent, or mixtures thereof.
[000115] The water used in the process described above is preferably
Demineralized water (DM water).
[000116] Preferably, the Varenicline base obtained according to the purification process described above has a total purity of greater than 97 percent or 98 percent by area HPLC, more preferably greater than 99 percent by area HPLC. Most preferably, the total purity is 99.97 percent.
[000117] Not to be limited to any mechanism, the above reaction mixture leads to phase separation of organic and aqueous phases. Preferably, Varenicline base may be recovered from the organic phase.
[000118] Optionally, Varenicline base obtained in the process described above is further precipitated from the reaction mixture using an organic solvent.
[000119] The precipitating organic solvent described above is a C5-C9 alkane.
Preferably the solvent is selected from a group consisting of pentane, hexane, and heptane. Most preferably, n-heptane is used.
[000120] Preferably, the Varenicline Tosylate used in the purification process described above, has a total purity of above 97 percent by area HPLC, more preferably above 99 percent. Most preferably, it is 99.99 percent
[000121] The base used in the purification process described above is selected from the group consisting of alkali metal and alkaline earth metal carbonates, hydroxides, organic bases, and aqueous ammonia. More preferably, the base is selected from lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide; C1-C4 alkyl amine, such as triethyl amine, diisopropyl amine, and diisopropyl ethyl amine; di- and tri-hydroxy
Ci-C4 alkyl amine; morpholine, piperidine, pyridine and pyrrolidine, and aqueous ammonia. Preferably, the base is selected from the group consisting of lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, and aqueous ammonia. Most preferably, the base is aqueous ammonia.
[000122] The inert solvent used in the process described above is selected from the group consisting OfC6-Cs aromatic hydrocarbons, C4-C6 esters, and Ci-C2 halogenated hydrocarbons. Preferably, the solvent is selected from the group consisting of xylene, which can be in the form of meta-xylene, ortho-xylene, para-xylene, and mixtures thereof, benzene, toluene, butyl acetate, isopropyl acetate, ethyl acetate, ethylene dichloride, methylene dichloride (MDC), carbon tetra chloride, chloroform, and combinations thereof. Most preferably, the inert solvent is MDC. [000123] The reaction mixture in the process described above is preferably maintained at a temperature of about 2O0C to about 6O0C. More preferably, the temperature is between about 2O0C to about 4O0C. Preferably, the reaction mixture in the above process is stirred for a period of about half an hour to about 2 hours, and, more preferably, at a temperature of about 250C to about 3O0C. [000124] Varenicline Tosylate can be combined with water and a base such as those described above. Preferably, first a solution of Varenicline Tosylate in water is prepared, followed by addition of the base to obtain a slurry. Varenicline can then be extracted into a water immiscible solvent. Examples of water immiscible solvents include C6-Cs aromatic hydrocarbons, C4-C6 esters and Ci-C2 halogenated hydrocarbons. Preferably, the solvent is selected from the group consisting of xylene (can be used is a form of meta-xylene, ortho-xylene, para-xylene, and mixtures thereof), benzene, toluene, butyl acetate, isopropyl acetate, ethyl acetate, ethylene dichloride, methylene dichloride (MDC), carbon tetra chloride, chloroform, and combinations thereof. Most preferably, MDC is used.
[000125] In one specific embodiment, 30 percent aqueous sodium hydroxide solution is added to a solution of Varenicline Tosylate in DM water, further combined with toluene, and maintained at a temperature of 50° to 600C for 30 minutes. Varenicline base is then extracted from the reaction mixture using toluene and n- heptane is added in order to precipitate Varenicline base as a solid material. [000126] The present invention also provides a process for preparing
Varenicline L-Tartrate, comprising preparing Varenicline Tosylate according to any of the processes described above, and converting the Varenicline Tosylate to Varenicline L-Tartrate. Preferably, the conversion of the Varenicline Tosylate to Varenicline L-Tartrate comprises converting the Varenicline Tosylate to Varenicline base according to any of the processes described above. Conversion of Varenicline base to Varenicline L-Tartrate may be obtained according to methods known in the art, such as the one described in U.S. Patents No. 6,890,927, incorporated herein by reference, wherein L-tartaric acid in methanol is combined with Varenicline base in methanol.
[000127] Varenicline base used in any of the processes described above may be obtained according to any known method in the art, such as the one described in US Patent No. 6,410,550, incorporated herein by reference, or according to examples 1 or 2 of the present application, wherein 1-(5,8,14-Triazatetracyclo[10.3.1.02'n.04'9] hexadeca-2(l l),3,5,9-pentaene)-2,2,2-trifluoro-ethanone in methanol is reacted with a base, e.g., alkali metal, alkaline earth metal carbonates or hydroxides, and then heated.
[000128] Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The disclosures of the references referred to in this patent application are incorporated herein by reference. The invention is further defined by reference to the following examples describing in detail the process and compositions of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
NMR analysis:
[000129] NMR spectra were taken on a Bruker Avance DRX 400 MHz
(frequency for 1H 400 MHz and for 13C 100.61 MHz) in DMSO-d6 solution at 398K. HPLC Methodology for the Impurity profile:
Preparation of Buffer:
[000130] 0.02M Ammonium Acetate and adjusted pH 9.0 with 10 percent ammonia solution. pH was measured with a pH meter (Model no. Cyber scan 510,
PC)
[000131] Preparation of mobile phase:
Mixture 70 percent of Buffer and 30 percent of Methanol (70:30), v/v)
Chromatographic conditions:
Column: X terra RP-18, 150 * 3.9 mm, 5μm
Flow: 0.5 ml/min
Injection Volume: 5.0 μl
Detector: 235 nm
Run time: 20 mins
Column Temperature: 30°C
Diluent: Buffer: methanol (70:30 v/v)
Autosampler temperature: 100C
XRD
Form I was analyzed on a Bruker X-Ray powder diffractometer Cu-tube, model D 8 advance equipped with lynxEye position sensitive detector or equivalent. Measurements were taken at a wavelength of Ka= 1.5406 Cu
Sample holder: a standard sample holder of PMMA. (In case of low amount of material, standard sample holder of PMMA was used with zero background plate).
Scanning parameters:
Sample: Spin mode, rotation speed: 60 rpm.
Range: 2-40 degrees two-theta.
Scan mode: Continuous scan.
Step size: 0.05±0.005 deg.
Time/Step: 0.1 sec. Divergon slit: 1 Procedure:
[000132] Sample preparation- Gently grind a small amount of powder in an agate mortar with the pestle. Fill the powder in the round cavity of the sample holder by pressing with a glass plate or equivalent, to form a smooth surface that its height will not deviate from the sample holder's height.
[000133] In the powder XRD measurements taken with silicon mixed with the
Varenicline Tosylate, the peak positions were calibrated using silicon powder as an internal standard in the admixture when the powder XRD of the sample was measured. The position of the silicon (111) peak was corrected to be 28.45 degrees two theta. The positions of Varenicline Tosylate forms I, II and IV peaks were corrected respectively. No correction was performed on the diffractograms presented in the figures.
[000134] Forms H-IV were analyzed on an ARL (Scintag) X-ray powder diffractometer model XTRA-019, Peltier detector, having a round standard aluminum sample holder with a round, zero background quartz plate. The cathode is CuKa radiation, λ = 1.5418 A.
[000135] Scanning parameters for measuring Forms II-IV without silicon and
Form rV with silicon: Range: 2-40 deg. 2 theta, continuous Scan, Rate: 3 deg/min, Step Size: 0.05. The accuracy of peak positions is defined as +/- 0.2 degrees.
[000136] Scanning parameters for Form I with silicon: Range: 2-40 deg. 2 theta, continuous Scan, Rate: 1 degree/minute, Step Size: 0.02. The accuracy of peak positions is defined as +/- 0.1 degrees.
[000137] Scanning parameters for measuring Form II with silicon: Range: 2-40 degrees 2 theta, continuous Scan, Rate: 3 deg/min, Step Size: 0.05. The accuracy of peak positions is defined as ± 0.1 degrees. Preparation of 5,8, 14-Triazatetracyclor 10.3.1.O2'11.04'91hexadeca-2( 11 ).3.5,7,9- pentaene (Varenicline Base) (comparative example to U.S. Patent No. 6,410,550 Example No. 26C, with an extra MDC extraction, up to reaction with HCL)
Example 1:
[000138] A suspension of 1-(5,8,14-Triazatetracyclo[10.3.1.02'n.04'9] hexadeca-2(l l)33,5,9-pentaene)-2,2,2-trifluoro-ethanone (4.0 g) (VRN 11) {HPLC purity 89.97%} in methanol was treated with an aqueous solution of sodium carbonate (2.76 g in 25 ml water). The mixture was warmed to 700C for 2 hours, and the progress of the reaction was monitored by TLC (MDC: MeOH 9:1). The solvent was distilled under vacuum at 55-6O0C to obtain an oily product, which was dissolved in water (250 ml). The above mixture was cooled to 25-300C, extracted with MDC (4 x 125 ml), and the aqueous layer was separated. The combined organic layer was filtered through a cotton plug, and concentrated to obtain an oily product, i.e. 5,8,14-Triazatetracyclo[10.3.1.02ll l.04'9]hexadeca-2(ll),3,5,7,9-pentaene (VRN-BASE) (Yield-1.92 g (72.67 % (relative to VRN-Il)), HPLC purity- 96.3 %,), which solidifies on standing.
I^aratJon of5.8.14-Triazatetracvclori0.3.1.02>n.04>91ha-adeca-2fin.3.5.7.9- pentaene (Varenicline Base) (Reference example)
Example 2:
[000139] A suspension of 1-(5,8,14-Triazatetracyclo[10.3.1.02'11.04>9] hexadeca-2(l l),3,5,9-pentaene)-2,2,2-trifiuoro-ethanone (20 g) (HPLC purity not lower than (NTL) 98%) in methanol (120 ml) was treated with an aqueous solution of sodium carbonate (13.8 g in 125 ml water). The mixture was warmed to 65° to 7O0C for 3 hours, and the reaction was monitored by HPLC. The methanol was completely distilled out under vacuum. The residue was dissolved in water (200 ml). The reaction mass was cooled to 25° to 300C, and extracted with MDC (5 x 100 ml.). The combined organic layer washed with DM water (2 x 100 ml). The organic layer was concentrated to the obtain product, i.e. Varenicline Base (Yield 12 g (87.20 % (relative to VRN-I I)), HPLC Purity NLT 98%). Preparation of 5.8.14-Triazatetracvclori0.3.1.02,l 1.04.91hexadeca-2(l 1),3,5,7,9- pentaene Tosylate (Varenicline Tosylate) form I
Example 3 :
[000140] A mixture of Isopropyl alcohol (1000 ml) and 5,8,14-
Triazatetracyclo[10.3.1.02>11.04>9]hexadeca-2(1 l),3,5,7,9-pentaene (Varenicline Base
(VRN Base), having a total purity of 96.89%) (100 g) was charged into the reactor at
25-3O0C. The obtained mixture was heated to 75-800C, and maintained at this temperature for 15 minutes. Then, p-Toluene sulfonic acid (p-TSA) (108.13g) was added at 70-750C, and the mixture was stirred for additional 15 minutes. The obtained reaction mass was cooled to 0-50C, and maintained at this temperature for 1 hour.
The obtained solid was filtered and washed with chilled (0-50C) isopropyl alcohol
(700 ml), and dried under vacuum at 50-550C to obtain 5,8,14-
Triazatetracyclo[10.3.1.02>11.04l9]hexadeca-2(ll),3,5,7,9-pentaene Tosylate that has an
HPLC purity-of 98.74%. Yield: 1.4-1.5 w/w (81.84 % (relative to VRN-Base)).
Example 4:
[000141] A suspension of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9] hexadeca-2(l l),3,5,7,9-pentaene (Varenicline Base, having a total purity of 98.65%) (1Og) in isopropyl alcohol (100 ml) was treated with p-TSA (10.8 g) at 70-750C. The mixture was stirred at 75-80 0C for 30 minutes, slowly (within one hour) cooled to 28- 32°C, and maintained for 2 hours. The crystallized solid was filtered, and the wet cake was washed with isopropyl alcohol (25 ml X 2). The product was then dried under vacuum at 50-550C for 10-15 hours. (Yield 13 g (68.78 % (relative to VRN-Base)), HPLC purity 99.42%)
Example 5:
[000142] A suspension of 5,8,14-Triazatetracyclo[10.3.1.02>n.04'9] hexadeca-
2(1 l),3,5,7,9-pentaene (Varenicline Base, having a total purity of 99.18%) (12Og) in Methanol (600 ml) was treated with para-toluene sulfonic acid (129.8 g) at 25-300C. The mixture was stirred at 65-700C for 60 minutes, and the reaction mass was slowly (for a period of 30 to 45 minutes) cooled to 28-32°C, and maintained for 2 hours. The crystallized solid was filtered, and the wet cake was washed with Methanol (120 ml). The product was dried under vacuum at 50-550C for 10-12 hours. (Yield 171.9 g (64.41 % (relative to VRN-Base)), HPLC purity 99.95%)
Example 6:
[000143] About 10 mg of Varenicline Tosylate form II was placed in closed crucible with three holes of the Differential Scanning Calorimeter (DSC) [Mettler Toledo DSC 82 le calorimeter] The sample was heated to 21O0C (at a heating rate of 1O0C /min). The sample was left to cool done to room temperature, and a powder XRD analysis was preformed. According to powder XRD diffractogram, Varenicline Tosylate form I was obtained.
Preparation of 5,8,14-Triazatetracvclori0.3.1.02J1.04,91hexadeca-2fl 1)3.5 ,7,9- pentaene Tosylate (Varenicline Tosylate) form II
Example 7:
[000144] To a clean and dry round bottom flask were charged methanol (600 ml) and 1-(5,8,14-Triazatetracyclo[10.3.1.02>11.04>9]hexadeca-2(l l),3,5,9-pentaene)- 2,2,2-trifluoro-ethanone, having a total purity of 98.43% (100 g), at 20-300C. To this suspension was added aqueous sodium hydroxide solution (26 g in 600 ml DM water) at 20-30°C in 1 hour. The reaction mixture was maintained for 1 hour at 20-300C, and the progress of the reaction was monitored by HPLC. After completion of the reaction, the temperature was raised to 50-600C, and a methanol and water (600 ml) mixture was distilled out under vacuum (50-100 mm Hg) at 50-600C. To the residue was added toluene (500 ml) at 50-600C, the mixture was maintained with stirring for 30 minutes, and the layers were separated at 50-600C. The aqueous layer was extracted with toluene (4x500 ml) at 50-600C. The combined organic layer was distilled under vacuum at 50-600C leaving 100 ml of toluene with the product. To the residue was added methanol (200 ml) at 45-55°C, and the mixture of toluene and methanol (200 ml) was distilled out under vacuum (50-100 mm Hg) at 50-600C. To the residue was charged methanol (200 ml) 45-550C, and the mixture of toluene and methanol (200 ml) was distilled out under vacuum (50-100 mm Hg) at 50-600C. To the residue were added methanol (140 ml), activated charcoal (6 g), and neutral aluminum oxide (6 g) at 45-55°C, and the mixture was heated to 65-700C and maintained for 1 hour. The resultant mixture was cooled to 45-550C, and filtered through a celite bed (20 g). The celite bed was washed with methanol (60 ml). To the filtrate obtained was charged p-toluene sulfonic acid (66 g) in organic layer at 45-550C, and maintained for 15 minutes. The temperature was raised to 65-7O0C, and maintained for 1 hour. The resultant mixture was cooled to 20-300C, and maintained for 2 hours. The solid crystallized was filtered at 20-30°C, and the wet cake was washed with methanol (60 ml). The obtained product was dried under vacuum at 45-55°C.
Yield: 0.85-0.95 w/w (72.94 % (relative to VRN-Il)). HPLC purity- 99.88%.
Preparation of 5,8J4-Triazatetracvclori0.3.1.02.11.04.91hexadeca-2(11),3,5J,9- pentaene Tosylate (Varenicline Tosylate) form III
Example 8:
[000145] About 200 mg of Varenicline Tosylate (Form IT) was exposed to 0 percent relative humidity (RH) for 7 days at room temperature. The resulting solid was analyzed by XRD, and shown to be a new Form (Form III).
Example 9:
[000146] About 200 mg of Varenicline Tosylate (Form II) was heated to 80° for one hour in an oven. The resulting solid was analyzed by XRD, and shown to be a new Form (Form III).
Example 10:
[000147] About 200 mg of Varenicline Tosylate Form II entered to humidity cell of 0% relative humidity for 2 days. The resulted material was measured by XRD. According to XRD pattern Form III was obtained
Preparation of 5,8 J4-Triazatetracvclori0.3.1.02 J 1.04,91hexadeca-2(l l),3,5J,9- pentaene Tosylate (Varenicline Tosylate) form TV Example 11:
[000148] A suspension of 1-(5,8,14-Triazatetracyclo[10.3.1.02'π.04'9] hexadeca-2(l l),3,5,9-pentaene)-2,2,2-trifluoro-ethanone (VRN-Il) (200 gm) (HPLC purity not lower than (NLT) 98%) in methanol (1200 ml) was treated with an aqueous solution of sodium carbonate (138.1 gm in 1250 ml water). The mixture was warmed to 65-700C for 2 hours. Progress of the reaction was monitored by TLC (methylene di-chloride (MDC): MeOH 9:1). Methanol was distilled out completely under vacuum, and the residue was dissolved in water (2000 ml). The reaction mass was cooled to 20° to 30°C, and extracted with MDC (4 x 100 ml.). The combined organic layer was washed with DM water (1 X 1000 ml). The organic layer was concentrated at 40° to 45°C, leaving 200 ml of MDC with the product. To the residue was added methanol (400 ml) at 40° to 450C, and the mixture of MDC and methanol (400 ml) was distilled out under vacuum (50 to 100 mm Hg) at 40° to 450C. To the residue was charged methanol (400 ml) at 40° to 45°C, and the mixture of MDC and methanol (200 ml) was distilled out under vacuum (50 to 100 mm Hg) at 40° to 450C. To the residue were charged methanol (200 ml) and para-toluene sulfonic acid (129.8 g) at 25° to 30 0C, the resultant mixture was heated to 65° to 700C, and maintained with stirring for 60 minutes. The reaction mass was slowly cooled to 25° to 300C in 1 hour, and maintained for 2 hours. The crystallized solid was filtered, and the wet cake was washed with Methanol (120 ml). The product was dried under vacuum at 45° to 550C for 10 to 12 hours. (Yield 171.9 gm (65.81% relative to VRN-Il)), HPLC purity 99.99%).
Example 12:
[000149] About 200 mg of Varenicline Tosylate (Form II) was ground with a drop of water for 1 minute with a mortar and pestle. The resulting solid was analyzed by XRD, and shown to be a new Form (Form IV).
Example 13:
[000150] About 200 mg of Varenicline Tosylate (Form II) was exposed to a range of 80 percent to 100 percent relative humidity (RH) for 7 days at room temperature. The resulting solid was analyzed by XRD, and shown to be a new Form (Form IV).
Example 14:
[000151] About 200 mg of Varenicline Tosylate Form II entered to humidity cell of 100% relative humidity for 1 day. The resulted material was measured by XRD. According to XRD pattern Form IV was obtained. Preparation of Varenicline-Base from Varenicline-Tosylate: Example 15:
[000152] A mixture of DM water (300 ml) and 5,8,14-Triazatetracyclo
[10.3.1.02'n.04'9]hexadeca~2(ll),3,5,7,9-pentaene Tosylate (100 g, having a total purity of 98.74 percent, obtained in example 3) was charged into a reactor at 25-300C, and stirred for 15 minutes. The pH was adjusted with aqueous ammonia (25 percent solution; 78 ml) to 9.5-10, and the contents were stirred at 25-3O0C for 2 hours. The material was extracted using dichloromethane (4x 300 ml). The combined organic layers were washed with 300 ml of water.
[000153] Dichloromethane was distilled under vacuum to obtain 5,8,14-
Triazatetracyclo[10.3.1.02ll l.04'9]hexadeca-2(ll),3,5,7,9-pentaene that has an HPLC purity-of 98.01 percent. Yield: 0.45-0.50 w/w (89.35 % (relative to VRN-Tosylate))
Example 16:
[000154] In a 250 ml 4 neck round bottom flask equipped with mechanical stirrer, Thermo pocket were charged DM water (30 ml) and 5,8,14-Triazatetracyclo [10.3.1.02,11.04,9]hexadeca-2(ll),3,5,7,9-pentaene Tosylate salt (10 g, having atotal purity of 99.42% obtained in example 4). The above suspension was stirred for 30 minutes at 25-30°C. To this was added 25 % aqueous ammonia solution (5 ml) to adjust the pH to 9.0-10 at 25-30°C, and MDC (30 ml) was added to this solution. The resulting mixture was stirred for 30 minutes at 20-250C. The organic layer was separated, and the aqueous layer was extracted with MDC (4x30 ml). The combined organic layer was washed with DM water (30 ml). The organic layer was treated with activated carbon (1.0 g), and stirred for 30 minutes at 25-300C. The resulting solution filtered through celite. Concentration afforded a solid product, i.e. 5,8,14- Triazatetracyclo[ 10.3.1.02, 11.04,9]hexadeca-2(ll),3,5,7,9-pentaene. (Yield-5 g (95.06 % (relative to VRN-Tosylate)), HPLC purity- 99.43 %).
Example 17:
[000155] A 250 ml 4 neck round bottom flask equipped with mechanical stirrer, Thermo pocket was charged with DM water (15 ml) and 5,8,14- Triazatetracyclo [ 10.3.1.02, 11.04,9]hexadeca-2(l 1 ),3,5,7,9-pentaene Tosylate salt (5 g, having a total purity of 99.71% ). The above suspension was stirred for 30 min at 25-300C. To this was added 8% aqueous sodium bicarbonate solution (150 ml) to adjust the pH to 8.0-9.0 at 25-300C. MDC (30 ml) was added to this solution. The resulting mixture was stirred for 30 minutes at 20-25°C. The organic layer was separated, and the aqueous layer was extracted with MDC (4X30 ml). The combined organic layer was washed with DM water (30 ml). The organic layer was treated with activated Carbon (1.0 g), and stirred for 30 minutes at 25-30 0C. The resulting solution was filtered through celite. Concentration afforded a solid product i.e. 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]hexadeca-2(ll),3,5,7,9-pentaene. (Yield- 2.5 g (95.06 % (relative to VRN-Tosylate)), HPLC purity- 99.65 %).
Example 18:
[000156] In a 3.0 lit 4 neck round bottom flask equipped with mechanical stirrer, Thermo pocket were charged DM water (507 ml) and 5,8,14-Triazatetracyclo [10.3.1.02>11.04'9]hexadeca-2(ll),3,5,7,9-pentaene tosylate salt (169 g having a total purity of 99.99% obtained in example 6). The above suspension was stirred for 30 minutes at 25-300C. To this was added 25 % aqueous ammonia solution (60 ml) to adjust the pH to 9.0-10 at 25-300C, and maintained with stirring for 30 minutes. MDC (507 ml) was charged in this solution. The resulting mixture was stirred for 30 minutes at 20-250C. The layers were separated, and the aqueous layer was extracted with MDC (4x507 ml). The combined organic layer washed with DM water (507 ml). The organic layer was treated with activated Carbon (16.9 g), and stirred for 30 minutes at 25-30 0C. The resulting solution was filtered through celite, concentrated to leave 1 volume of MDC with product, charged with 845 ml n-heptane at 45-500C, and distilled under vacuum to remove a mixture of MDC and n-heptane to leave 3 volumes of n-heptane. The solid material was cooled to 25-3O0C, and filtered at 25-300C to afford a solid product, i.e. 5,8,14-Triazatetracyclo[10.3.1.02>11.04'9] hexadeca-2(l l),3,5,7,9-pentaene. The solid obtained was dried in vacuum oven at 45° to 500C. (Yield-84g (94.49 % (relative to VRN-Tosylate)), HPLC purity- 99.97%).
Example 19:
[000157] A clean and dry round bottom flask was charged with DM water (300 ml) and 5,8,14-Triazatetracyclo[10.3.1.02'n.04>9]hexadeca-2(11),3)5,7,9- pentaene tosylate salt (10Og, having a total purity of 99.94%) at 20-300C. The pH of the mixture was adjusted to 12.5-13.5 using 30% aqueous sodium hydroxide solution (50 ml) at 20-30°C, and maintained for 30 minutes. To the clear solution obtained was charged toluene (500 ml) at 20-300C, and the temperature was raised to 50-600C, and maintained for 30 minutes. The aqueous layer was separated, and the pH was adjusted to 12.5-13.5, and the layer was extracted with toluene (4X500 ml) at 50-600C. To the combined organic layers were charged activated carbon (10 g) and neutral aluminum oxide (10 g) at 50-600C. The resulting mixture was stirred for 60 minutes at 50-600C, filtered through a celite bed (20 g) at 50-600C, and the celite bed was washed with toluene (200 ml). The filtrate was distilled out under vacuum (50-100 mm Hg) at 50-600C leaving 200 ml toluene with compound. To the residue was charged n-heptane (200 ml) at 50-600C, and a mixture of n-heptane and toluene (200 ml) was distilled out under vacuum (50-100 mm Hg) at 50-600C. Again, n-heptane (200 ml) was charged to the residue at 50-60°C, and a mixture of n-heptane and toluene (200 ml) was distilled out under vacuum (50-100 mm Hg) at 50-600C. To the resultant slurry was charged n-heptane (100 ml) at 50-600C, and the resulting mixture was cooled to 20-300C and maintained for 1 hour. The precipitated solid was filtered and washed with n-heptane (100 ml) at 20-300C. The wet cake was dried under vacuum (20-50 mm Hg) at 50-600C for 10-12 hours.
Yield: 0.45-0.50 w/w (91.25 % (relative to VRN-Tosylate)). HPLC purity 99.97%.

Claims

What is Claimed:
1. A process for purifying Varenicline base, comprising: converting a Varenicline base starting material to Varenicline Tosylate; and converting the Varenicline Tosylate to a Varenicline base product; wherein the Varenicline base product has a purity greater than the purity of the Varenicline base starting material.
2. The process of claim I5 further comprising, reacting the Varenicline base starting material with p-Toluene sulfonic acid to convert the Varenicline base starting material to Varenicline Tosylate.
3. The process of either of claims 1 and 2, further comprising, slurrying the Varenicline Tosylate in water with a base and inert organic solvent to convert the Varenicline Tosylate to the Varenicline base product.
4. A process for obtaining purified Varenicline base, comprising slurrying Varenicline Tosylate in water with a base and an inert organic solvent.
5. A process for obtaining purified Varenicline base, having a total purity of greater than about 98.5 percent by area HPLC, comprising combining a Varenicline Tosylate in water with a base in the presence of an inert organic solvent.
6. The process of any of claims 1 to 5, further comprising recovering the purified Varenicline base.
7. The process of any of claims 1 to 6, wherein the Varenicline Tosylate is in crystalline form I, π, III, IV, or mixtures thereof.
8. The process of any of claims 1 to 7, wherein the Varenicline Tosylate has a total purity of greater than 97 percent by area HPLC.
9. The process of any of claims 1 to 8, wherein the purified Varenicline base is precipitated from the reaction mixture with an organic solvent.
10. The process of claim 9, wherein the organic solvent is a C5-C9 alkane.
11. The process of claim 10, wherein the organic solvent is selected from the group consisting of pentane, hexane, heptane.
12. The process of claim 11, wherein the organic solvent is n-heptane.
13. The process of any of claims 3 to 12, wherein the base is selected from the group consisting of alkali metal and alkaline earth metal carbonates, hydroxides, organic bases and aqueous ammonia.
14. The process of any of claims 3 to 12, wherein the base is selected from the group consisting of lithium carbonate, sodium carbonate, sodium bicarbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, triethyl amine, diisopropyl amine, diisopropyl ethyl amine, di- and tri-hydroxy Ci-C4 alkyl amine, morpholine, piperidine, pyridine and pyrrolidine, and aqueous ammonia.
15. The process of any of claims 3 to 12, wherein the base is aqueous ammonia.
16. The process of any of claims 3 to 15, wherein the inert solvent is selected from the group consisting of Ce-C8 aromatic hydrocarbons, C4-C6 esters, and Ci-C2 halogenated hydrocarbons.
17. The process of any of claims 3 to 15, wherein the inert solvent is selected from the group consisting of xylene, benzene, toluene, butyl acetate, isopropyl acetate, ethyl acetate, ethylene dichloride, methylene dichloride, carbon terra chloride, and chloroform.
18. The process of any of claims 3 to 15, wherein the inert solvent is methylene dichloride.
19. The process of any of claims 3 to 18, further comprising, conducting the process at a temperature of about 2O0C to about 6O0C.
20. The process of any of claims 3 to 18, further comprising, conducting the process at a temperature of about 250C to about 3O0C.
21. Varenicline Tosylate, having a total purity of greater than about 97 percent by area HPLC.
22. The Varenicline Tosylate of claim 21 , having a total purity of greater than about 99 percent by area HPLC.
23. The Varenicline Tosylate of claim 21 , having a total purity of about 99.99 percent by area HPLC.
24. Varenicline base, having a total purity of greater than about 98.5 percent by area HPLC.
25. The Varenicline base of claim 24, having a total purity of greater than about 99 percent by area EDPLC.
26. The Varenicline base of claim 24, having a total purity of about 99.97 percent by area HPLC.
27. A crystalline form of Varenicline Tosylate, designated form I, characterized by data selected from the group consisting of: a powder XRD pattern having peaks at about 10.1, 13.0, and 18.7 ± 0.2 degrees two theta and at least two peaks selected from the group consisting of 11.5, 14.2, 16.7, 19.3, and 20.6 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 10.1, 13.0, 16.7, 18.7 and 20.6 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 10.2, 13.1, 16.8, 19.4, 23.0 ± 0.1 degrees two theta; a powder XRD pattern substantially as depicted in Figures 4 and 5; and combinations thereof.
28. The crystalline form of claim 27, characterized by a powder XRD pattern having peaks at about 10.1, 13.0, 16.7, 18.7, and 20.6 ± 0.2 degrees two theta.
29. The crystalline form of claim 27, characterized by a powder XRD pattern having peaks at about 10.2, 13.1, 16.8, 19.4, 23.0 ± 0.1 degrees two theta.
30. The crystalline form of claim 27, further characterized by powder XRD peaks selected from a group consisting of: a powder XRD pattern having peaks at about 11.5, 14.2, 17.4, 19.3, and 22.3 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 14.3, 18.5, 18.9, 23.5 and 26.8 ± 0.1 degrees two theta; and combinations thereof.
31. A process for preparing the Varenicline Tosylate crystalline form of claim 27, comprising: combining Varenicline Base, a Ci-Cs alcohol, and p-Toluene sulfonic acid to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture.
32. A process for preparing the Varenicline Tosylate crystalline form of claim 27, comprising: heating a mixture of Varenicline Base in a Ci-C6 alcohol and p-Toluene sulfonic acid, and cooling the mixture.
33. The process of any of claims 31 to 32, wherein the Ci-C6 alcohol is iso-propyl alcohol or methanol.
34. The process of any of claims 31 to 32, wherein the alcohol is methanol.
35. The process of any of claims 31 to 34, wherein the reaction mixture is heated to a temperature of about 650C to about 85°C.
36. The process of any of claims 31 to 34, wherein the reaction mixture is heated to a temperature of about 65°C to about 7O0C.
37. The process of any of claims 31 to 36, wherein the reaction mixture is cooled to a temperature of about 350C to about 00C.
38. The process of any of claims 31 to 36, wherein the reaction mixture is cooled to a temperature of about 32°C to 28°C.
39. A process for preparing the Varenicline Tosylate crystalline form of claim 27, comprising: heating Varenicline Tosylate form II for a period sufficient to convert form II to form I.
40. The process of claim 39, wherein heating is to a temperature of about 190°C to about 215°C.
41. The process of claim 39, wherein heating is to a temperature of about 2100C.
42. A crystalline form of Varenicline Tosylate, designated form II, characterized by data selected from the group consisting of: a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 20.8, and 21.3 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 21.3, and 23.3 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 5.8, 10.0, 17.4, 19.1, 23.3 ± 0.1 degrees two theta; a powder XRD pattern substantially as depicted in Figures 6 and 7; and combinations thereof.
43. The crystalline form of claim 42, characterized by a powder XRD pattern having peaks at about 11.6, 12.9, 13.3, 21.3, and 23.3 ± 0.2 degrees two theta.
44. The crystalline form of claim 42, characterized by a powder XRD pattern having peaks at about 5.8, 10.0, 17.4, 19.1, 23.3 ± 0.1 degrees two theta.
45. The crystalline form of claim 42, further characterized by powder XRD pattern peaks selected from a group consisting of; a powder XRD pattern having peaks at about 5.8, 10.0, 16.9, 17.4, and 18.8 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 11.5, 13.2, 20.8, 22.5 and 25.4 ± 0.1 degrees two theta; and combinations thereof.
46. A process for preparing the Varenicline Tosylate crystalline form of claim 42, comprising: combining Varenicline Base, methanol, a Cg-Ci2 aromatic hydrocarbon, and p-Toluene sulfonic acid to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture.
47. A process for preparing the Varenicline Tosylate crystalline form of claim 42, comprising: heating a mixture of Varenicline base in methanol, CQ-CU aromatic hydrocarbon, and p-Toluene sulfonic acid, and cooling the mixture.
48. The process of any of claims 46 to 47, wherein the CrCi2 aromatic hydrocarbon is toluene or xylene.
49. The process of any of claims 46 to 47, wherein the Ce-C12 aromatic hydrocarbon is toluene.
50. The process of any of claims 46 to 49, wherein Varenicline base and p- Toluene sulfonic acid are combined in a mixture of about 15 percent to about 30 percent volume C6-Ci2 aromatic hydrocarbon and about 70 percent to about 85 percent volume methanol.
51. The process of any of claims 46 to 49, wherein the reaction mixture is heated to a temperature of from about 65°C to about 700C.
52. The process of any of claims 46 to 51 , wherein the reaction mixture is cooled to a temperature of from about 3O0C to about 200C.
53. A crystalline form of Varenicline Tosylate, designated form III, characterized by a powder XRD pattern having peaks at about 10.0, 11.6, 17.4, 22.3, and 22.8 ± 0.2 degrees two theta.
54. The crystalline form of claim 53, further characterized by data selected from the group consisting of: apowder XRD pattern peaks at about 5.8, 18.8, 19.3, 20.8, and 23.2 ± 0.2 degrees two theta; a powder XRD pattern having peaks at about 5.9, 18.9, 19.3, 20.8 and 26.4 ± 0.2 degrees two theta; and combinations thereof.
55. The crystalline form of any of claims 53 to 54, further characterized by a powder XRD diffraction pattern, depicted in Figures 8, 9 and/or 10.
56. A process for preparing the Varenicline Tosylate crystalline form of claim 53, comprising exposing Varenicline Tosylate crystalline form II to less than about 5 percent relative humidity, for a period sufficient to convert form II to form DI.
57. The process of claim 56, wherein the relative humidity is 0 percent.
58. The process of claim 56 or 57, wherein the Varenicline Tosylate crystalline form II is exposed for a period of about 1 to about 15 days.
59. The process of any of claims 56 to 58, wherein the Varenicline Tosylate crystalline form π is exposed for a period of 2 days.
60. A process for preparing the Varenicline Tosylate crystalline form of claim 53, comprising heating Varenicline Tosylate crystalline form II for a period sufficient to convert form II to form III.
61. The process of claim 60, wherein the Varenicline Tosylate crystalline form II is heated to a temperature of about 7O0C to about 100°C.
62. The process of claim 60, wherein the Varenicline Tosylate crystalline form II is heated to a temperature of about 8O0C.
63. The process of any of claims 60 to 62, wherein the Varenicline Tosylate crystalline form II is heated for a period of about half an hour to about two hours.
64. A crystalline form of Varenicline Tosylate, designated form IV, characterized by a powder XRD pattern having peaks at about 11.6, 13.2, 19.5, 23.0, and 24.4 ± 0.2 degrees two theta as depicted in the powder XRD diffraction of Figures 11 , 12, and 13.
65. The crystalline form of claim 64, further characterized by powder XRD pattern peaks at about 10.3, 16.9, 18.9, 20.7, and 22.5 ± 0.2 degrees two theta.
66. A process for preparing Varenicline Tosylate form IV, comprising combining, Varenicline base, a Ci-C6 alcohol, a Ci-C3 halogenated aliphatic hydrocarbon and p-Toluene sulfonic acid to obtain a reaction mixture, and heating and then cooling the obtained reaction mixture.
67. The process of claim 66, wherein the Ci-C6 alcohol is isopropyl alcohol or methanol.
68. The process of claim 66, wherein the CrC6 alcohol is methanol.
69. The process of any of claim 66 to 68, wherein the Ci-C3 halogenated aliphatic hydrocarbon is methylene di-chloride or ethylene dichloride.
70. The process of any of claim 66 to 68, wherein the Ci-C3 halogenated aliphatic hydrocarbon is methylene di-chloride.
71. The process of any of claim 66 to 70, wherein the reaction mixture is heated to a temperature of about 650C to about 75°C.
72. The process of any of claim 66 to 71 , wherein the reaction mixture is cooled to a temperature of about 300C to 25°C.
73. A process for preparing the Varenicline Tosylate crystalline form of claim 64, comprising wetting Varenicline Tosylate crystalline form II with water, and grinding the wetted material.
74. The process of claim 73, wherein the wet Varenicline Tosylate is ground for a period of about 1 minute to about 5 minutes.
75. The process of claim 73, wherein the wet Varenicline Tosylate is ground for a period of about 1 minute.
76. A process for preparing the Varenicline Tosylate crystalline form of claim 64, comprising exposing Varenicline Tosylate crystalline form II to a relative humidity of from about 80 percent to about 100 percent for a period sufficient to convert the form II to form IV.
77. The process of claim 76, wherein Varenicline Tosylate form II is exposed for a period of about 1 to about 15 days.
78. The process of claim 76, wherein Varenicline Tosylate form II is exposed for a period of about 1 day.
79. A process for preparing Varenicline L-Tartrate, comprising preparing Varenicline Tosylate according to any of claims 1 to 20, 31 to 41, 46 to 52, 56 to 63, and 66 to 78, and converting the Varenicline Tosylate to Varenicline L-Tartrate.
80. The process of claim 79, further comprising converting the Varenicline Tosylate to Varenicline base, and converting the Varenicline base to Varenicline L-Tartrate.
EP09751575A 2008-05-22 2009-05-21 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate Withdrawn EP2268639A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12864908P 2008-05-22 2008-05-22
US13535908P 2008-07-17 2008-07-17
US19028408P 2008-08-26 2008-08-26
US15339009P 2009-02-18 2009-02-18
PCT/US2009/044844 WO2009143347A2 (en) 2008-05-22 2009-05-21 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate

Publications (1)

Publication Number Publication Date
EP2268639A2 true EP2268639A2 (en) 2011-01-05

Family

ID=41202519

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09751575A Withdrawn EP2268639A2 (en) 2008-05-22 2009-05-21 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate

Country Status (5)

Country Link
US (1) US8039620B2 (en)
EP (1) EP2268639A2 (en)
CA (1) CA2709774C (en)
IL (1) IL209323A0 (en)
WO (1) WO2009143347A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438054A1 (en) * 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof
US20130101630A1 (en) * 2010-03-09 2013-04-25 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
KR101781352B1 (en) 2016-09-23 2017-10-23 경동제약 주식회사 Crystalline forms of novel varenicline salts, preparation methods thereof and pharmaceutical compositions comprising thereof
CN112384504A (en) 2018-06-15 2021-02-19 R.J.雷诺兹烟草公司 Purification of nicotine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605610B1 (en) 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
DE122008000038I1 (en) 1997-12-31 2008-11-13 Pfizer Prod Inc ARYL CONDENSED AZAPOLYCYCLIC DERIVATIVES
WO2001072695A1 (en) * 2000-03-28 2001-10-04 Takeda Chemical Industries, Ltd. Neovascularization inhibitors
EP1280775A1 (en) 2000-05-12 2003-02-05 Synthon B.V. TOSYLATE SALTS OF 4-(p-FLUOROPHENYL)-PIPERIDINE-3-CARBINOLS
CZ20011726A3 (en) 2000-05-26 2002-02-13 Pfizer Products Inc. Reactive crystallization process enabling the control of particle size
CN1494422A (en) 2001-03-01 2004-05-05 �Ʒ� Use of GABAA inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin E for treatment of cognitive disorders
KR100551183B1 (en) 2001-04-20 2006-02-13 화이자 프로덕츠 인크. Process for the Preparation of 1,3-Substituted Indenes and Aryl-Fused Azapolycyclic Compounds
PT1392307E (en) 2001-05-14 2005-11-30 Pfizer Prod Inc SALTS 5,8,14-TRIAZATETRACYCLO [10.3.1.02,11.04,9] -HEXADECA-2 (11), 3,5,7,9-PENTAENE
NZ528209A (en) 2001-05-14 2004-09-24 Pfizer Prod Inc The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
US20030134844A1 (en) 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
RU2004116311A (en) 2001-11-29 2005-03-27 Пфайзер Продактс Инк. (Us) SUCCINATE SALTS 5,8,14-TRIAZETETRACYCLO [10.3.1.02,11 (04,9] HEXADECA-2 (11), 3,5,7,9-PENTAENE AND THEIR PHARMACEUTICAL COMPOSITIONS
ES2282492T3 (en) 2001-11-30 2007-10-16 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION ORALS 5,8,14-TRIAZATETRACICLO (10.3.1.0 (2,11) .0 (4,9) -HEXADECA-2 (11) 3,5,7,9-PENTAENO.
US20060057207A1 (en) 2001-11-30 2006-03-16 Pfizer Inc Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
EP1961737A1 (en) 2002-11-20 2008-08-27 Pfizer Products Inc. Indan-1,3-carbodinitrile dervatives
WO2004048318A1 (en) 2002-11-25 2004-06-10 Pfizer Products Inc. Improved process for the preparation of 1,3-substituted indenes
WO2004063164A1 (en) 2003-01-15 2004-07-29 Pfizer Products Inc. Process for the preparation of aryl fused polycyclic lactams
WO2004103372A1 (en) 2003-05-20 2004-12-02 Pfizer Products Inc. Pharmaceutical compositions of varenicline
WO2004108725A1 (en) 2003-06-04 2004-12-16 Pfizer Products Inc. Preparation of substituted quinoxalines from the dianline with 2,3-dihydroxy-1,4-dioxane
CA2583101A1 (en) 2004-10-15 2006-04-20 Pfizer Products Inc. Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
KR20070098942A (en) 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 Preparation of high purity substituted quinoxaline
JP2008533194A (en) 2005-03-21 2008-08-21 ファイザー・プロダクツ・インク Varenicline chewing gum composition
JP2008541037A (en) 2005-05-04 2008-11-20 ファイザー・プロダクツ・インク Detection of orthodiamine residues in specimens containing residual cyclizing agents
US20110086086A1 (en) 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
EP2004186A2 (en) 2006-03-27 2008-12-24 Pfizer Products Inc. Varenicline standards and impurity controls
BRPI0710914A2 (en) 2006-04-24 2011-09-27 Pfizer Prod Inc dosage form and method for the treatment of nicotine addiction, addiction and suppression, in particular for use in smoking cessation therapy
KR20090086071A (en) 2006-11-09 2009-08-10 화이자 프로덕츠 인코포레이티드 Polymorphs of nicotinic intermediates
WO2009065872A2 (en) 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
WO2009109651A1 (en) 2008-03-06 2009-09-11 Medichem, S.A. SALTS OF A PYRAZINO[2,3-h][3]BENZAZEPINE DERIVATIVE
US8314235B2 (en) 2008-09-01 2012-11-20 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof
EP2438054A1 (en) 2009-06-22 2012-04-11 Teva Pharmaceutical Industries Ltd. Solid states forms of varenicline salts and processes for preparation thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009143347A2 *

Also Published As

Publication number Publication date
IL209323A0 (en) 2011-01-31
WO2009143347A3 (en) 2010-05-06
CA2709774C (en) 2012-10-02
CA2709774A1 (en) 2009-11-26
US20100004451A1 (en) 2010-01-07
US8039620B2 (en) 2011-10-18
WO2009143347A9 (en) 2010-07-29
WO2009143347A2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CA2709774C (en) Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20120022124A1 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
EP1461040B1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
US7781427B2 (en) Process for preparing quinoline compounds and products obtained therefrom
US20070203176A1 (en) Crystalline forms of dolasetron base and processes for preparation thereof
WO2012081031A1 (en) Process for preparing tetrabenazine
WO2008087557A2 (en) An improved process for preparation of 9-hydroxy-3-(2-chloroethyl)- 2-methyl-4h-pyrido[1,2-a]pyrimidin-4-one hydrochloride
EP2729470B1 (en) Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
CN114437084B (en) Heterocyclic compound and preparation method and application thereof
US7547785B2 (en) Process for preparing topotecan
WO2008114279A2 (en) Novel polymorphs of lamivudine
US20090137821A1 (en) Method of making dorzolamide hydrochloride
JP3930736B2 (en) Method for producing pyridinemethanol compound
WO2009044413A2 (en) Improved process for preparing paliperidone, novel polymorphic forms of the same and process thereof
US7745429B2 (en) Crystal forms of olanzapine and processes for their preparation
US20080097100A1 (en) Opiate Intermediates and Methods of Synthesis
EP2229387A1 (en) Process for preparing chemically and chirally pure solifenacin base and its salts
US20080269495A1 (en) Process for Preparation of Piperidine Carboxylic Acid
JP4994772B2 (en) Method for producing piperidin-4-one derivative using bisaminol ether compound
US20080269493A1 (en) Crystalline forms of topotecan hydrochloride and processes for making the same
WO2004083213A1 (en) 4,6-dihydrofuro[3,4-d]imidazole-6-one derivatives and their salts and process for the preparation of the same
WO2004065381A1 (en) Process for making ondansetron and intermediates thereof
CN109836400A (en) The preparation method of heterocyclic compound and its salt
US20050171145A1 (en) Process for the preparation of 2-(ethoxymethyl)-tropane derivatives
WO2003027106A1 (en) Process for the preparation of crystalline polymorph ii of lamivudine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101025

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131203